Home > Healthcare > Biotechnology > Biopharma > Cancer Gene Therapy Market

Cancer Gene Therapy Market Share

Report ID: GMI763
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Cancer Gene Therapy Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for effective cancer gene therapy.

Cancer Gene Therapy Market Companies

Prominent players operating in the cancer gene therapy industry are as mentioned below:

Abeona Therapeutics Inc.
Altor Bioscience Inc.
Asklepios BioPharmaceutical Inc.
Bluebird bio, Inc.
Bristol-Myers Squibb Company
Elevate Bio
Genelux Corporation
GSK plc
Introgen Therapeutics Inc.
Merck KGaA
Novartis AG

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global cancer gene therapy market was valued at USD 2.2 billion in 2023 and is expected to reach USD 11.8 billion by end of 2032, driven by rising prevalence of cancer cases and the growing need for gene therapy.

The biopharmaceutical companies segment in the cancer gene therapy industry is expected to exhibit 21% CAGR between 2024 – 2032, propelled by the growing utilization of fundamental gene therapy approaches to develop cancer treatment regimens.

North America cancer gene therapy market secured a substantial share of 43.7% in 2023, attributed to the significant investment in R&D, presence of key players, and collaborations between biopharmaceutical companies, research institutions, and healthcare providers.

Abeona Therapeutics Inc., Altor Bioscience Inc., Asklepios BioPharmaceutical Inc., Bluebird bio, Inc., Bristol-Myers Squibb Company, Elevate Bio, Genelux Corporation, GSK plc, Introgen Therapeutics Inc., Merck KGaA and Novartis AG